DUPLICATION, MULTIDUPLICATION, AND AMPLIFICATION OF GENES ENCODING DRUG-METABOLIZING ENZYMES: EVOLUTIONARY, TOXICOLOGICAL, AND CLINICAL PHARMACOLOGICAL ASPECTS

REFERENCES

• Bertz R. J., Granneman G. R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 1997; 32: 210–258
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Dahl M. L., Sjöqvist F., Åberg-Wistedt A., Humble M., Johansson I., Lundqvist E., Ingelman-Sundberg M. Molecular basis for rational mega prescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63
   PubMed Web of Science ®Google Scholar
• Johansson I., Lundqvist E., Bertilsson L., Dahl M. L., Sjöqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 1993; 90: 11825–11829
   PubMed Web of Science ®Google Scholar
• Yue Q. Y., Bertilsson L., Dahl-Puustinen M. L., Säwe J., Sjöqvist F., Johansson I., Ingelman-Sundberg M. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet 1989; 2: 870
   PubMed Web of Science ®Google Scholar
• Johansson I., Oscarson M., Yue Q. Y., Bertilsson L., Sjöqvist F., Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 1994; 46: 452–459
   PubMed Web of Science ®Google Scholar
• Mura C., Broyard J. P., Jacqz-Aigrain E., Krishnamoorthy R. Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese. Br. J. Clin. Pharmacol. 1991; 32: 135–136
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Âberg-Wistedt A., Gustafsson L. L., Nordin C. Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther. Drug. Monit. 1985; 7: 478–480
   PubMed Web of Science ®Google Scholar
• Hei M. H., Meyer U. A. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992; 14: 49–58
   PubMed Web of Science ®Google Scholar
• Roots I., Drakoulis N., Brockmöller J. Polymorphic enzymes and cancer risk: Concepts, methodology and data review, in Pharmacogenetics of Drug Metabolism, W. Kalow. Pergamon Press, Elmsford, NY 1992; 815–842
   Google Scholar
• Aklillu E., Persson I., Bertilsson L., Johansson I., Rodrigues F., Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 1996; 278: 441–446
   PubMed Web of Science ®Google Scholar
• McLellan R. A., Oscarson M., Seidegård J., Evans D. A., Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 187–191
   PubMedGoogle Scholar
• Agundez J. A., Ledesma M. C., Ladero J. M., Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 1995; 57: 265–269
   PubMed Web of Science ®Google Scholar
• Dahl M. L., Johansson I., Bertilsson L., Ingelman-Sundberg M., Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 1995; 274: 516–520
   PubMed Web of Science ®Google Scholar
• Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997; 60: 284–295
   PubMed Web of Science ®Google Scholar
• Agundez A. J., Ramirez R., Hernandez M., Llerena A., Benitez J. Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: Impact of gene-flow from Europe. Pharmacogenetics 1997; 7: 337–340
   PubMedGoogle Scholar
• Bathum L., Johansson I., Ingelman-Sundberg M., Horder M., Broder K. Ultrarapid metabolism of sparteine: Frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by RFLP and long PCR. Pharmacogenetics 1998; 8: 119–123
   PubMedGoogle Scholar
• Masimirembwa C. M., Johansson I., Hasler J. A., Ingelman-Sund-berg M. Genetic polymorphism of cytochrome P450 CYP2D6 in a Zimbabwean population. Pharmacogenetics 1993; 3: 275–280
   PubMedGoogle Scholar
• Roh H.-K., Dahl M.-L., Johansson I., Ingelman-Sundberg M., Cha Y.-N., Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6: 441–447
   PubMedGoogle Scholar
• London S. J., Daly A. K., Leathart J. B., Navidi W. C., Carpenter C. C., Idle J. R. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 1997; 18: 1203–1214
   PubMed Web of Science ®Google Scholar
• Ruiz M. L. Berna, Johansson I., Dalén P., Dahl M.-L., Ingelman-Sund-berg M., Bertilsson L. Gene duplication of CYP2D6 in a Spanish population. Pharmacogenetics, (in press)
   Google Scholar
• Fonne-Pfister R., Meyer U. A. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem. Pharmacol. 1988; 37: 3829–3835
   PubMed Web of Science ®Google Scholar
• Lundqvist E., Johansson I., Ingelman-Sundberg M. Characterization of the CYP2D allelic locus containing duplicated functional CYP2D6 genes. Allele specific PCR analysis for determination of ultrarapid metabolizers, Gene, (in press)
   Google Scholar
• Lovlie R., Daly A. K., Molven A., Idle J. R., Steen V. M. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996; 392: 30–34
   PubMed Web of Science ®Google Scholar
• McLellan R. A., Oscarson M., Alexandrie A.-K., Seidegârd J., Evans D. A. P., Rannug A., Ingelman-Sundberg M. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene causing ultrarapid enzyme activity. Mol. Pharmacol. 1997; 52: 958–965
   PubMed Web of Science ®Google Scholar
• Dalén P., Dahl M.-L., Ruiz M. L. Berna, Nordin J., Bertilsson L. 10-Hydroxylation of nortriptyline in Caucasians with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 1998; 63: 444–452
   PubMed Web of Science ®Google Scholar
• Tyndale R. F., Droll K. P., Sellers E. M. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7: 375–379
   PubMedGoogle Scholar
• Aynacioglu A. S., Sachse C., Brockmöller J., Kayaalp O. S., Bozkurt A., Basci N. E., Tapanyigit E. E., Nacak M., Roots I. Allele frequencies of CYP2D6 and CYP2C19 in a Turkish population, in Microsomes, Drug Oxidation, and Clinical Pharmacology, a Satellite Symposium to the 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin, 1997, [Abstract]
   Google Scholar